<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04460729</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280A2203</org_study_id>
    <nct_id>NCT04460729</nct_id>
  </id_info>
  <brief_title>A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases</brief_title>
  <official_title>A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, Non Small-Cell Lung Cancer That Has Metastasized to the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the intracranial efficacy of single agent&#xD;
      capmatinib in the population of treatment-naïve or pretreated with one or two prior lines of&#xD;
      systemic therapies for advanced stage Non Small-Cell Lung Cancer (NSCLC) with MET exon 14&#xD;
      mutation that has metastasized to the brain.&#xD;
&#xD;
      Cohort 1 (asymptomatic brain metastases (BM) without prior brain therapy) has been selected&#xD;
      to identify patients who are most likely to benefit from capmatinib therapy in this setting&#xD;
      and to establish a clinically relevant response outcome.&#xD;
&#xD;
      Cohort 2 is a heterogeneous group of patients (symptomatic with and without prior brain&#xD;
      therapy, asymptomatic with prior brain therapy, or with leptomeningeal disease.), and the&#xD;
      outcomes will be descriptive only&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospectively designed, multicenter, open-label, two-cohort, phase II study to&#xD;
      evaluate the intracranial efficacy of single agent capmatinib in participants with MET exon&#xD;
      14 mutated NSCLC and BM. Participants can be treatment naïve or pretreated with one or two&#xD;
      prior lines of systemic therapies for advanced stage (stage IIIb - IV) NSCLC.&#xD;
&#xD;
      Approximately 60 participants will be enrolled globally and allocated to one of two cohorts:&#xD;
&#xD;
      Cohort 1 will enroll approximately 40 participants who are asymptomatic and without prior&#xD;
      brain therapy.&#xD;
&#xD;
      Cohort 2 will enroll approximately 20 participants who are symptomatic with or without prior&#xD;
      brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease.&#xD;
&#xD;
      All participants will be pre-screened for MET mutation and presence of BM will be documented&#xD;
      at baseline by a radiologist/neuroradiologist.&#xD;
&#xD;
      Intracranial disease will be assessed and response to treatment will be evaluated using the&#xD;
      Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria every 8 weeks.&#xD;
      Extracranial and whole body disease will be assessed and response to treatment will be&#xD;
      evaluated using RECIST 1.1 every 8 weeks.&#xD;
&#xD;
      Participants will receive capmatinib 400 mg b.i.d. until they experience any of the&#xD;
      following: documented disease progression by RANO-BM criteria and/or RECIST 1.1 (as assessed&#xD;
      by the investigator and confirmed by BIRC), withdrawal of consent, pregnancy, lost to&#xD;
      follow-up, or death.&#xD;
&#xD;
      For all participants, treatment with capmatinib may be continued beyond initial progression&#xD;
      disease (PD) as per RANO-BM criteria and/or RECIST 1.1 (as assessed by the investigator and&#xD;
      confirmed by BIRC) if, in the judgment of the investigator, there is evidence of clinical&#xD;
      benefit, and the participant wishes to continue on the study treatment.&#xD;
&#xD;
      After treatment discontinuation, all participants will be followed for safety evaluations&#xD;
      during the safety follow-up period, and the participant's status will be collected every 12&#xD;
      weeks as part of the survival follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    company decision&#xD;
  </why_stopped>
  <start_date type="Anticipated">November 11, 2020</start_date>
  <completion_date type="Anticipated">November 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Approximately 60 participants will be enrolled globally and allocated to one of two cohorts based on whether their metastatic brain disease is symptomatic or asymptomatic and with or without prior brain therapy or if they have been diagnosed with leptomeningeal disease</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Intracranial Response Rate (OIRR) in Cohort 1 by Blinded Independent Review Committee (BIRC) review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Overall Intracranial Response Rate (OIRR) in Cohort 1, defined as the proportion of participants with a confirmed best intracranial overall response of Complete Response (CR) or Partial Response (PR) per RANO-BM criteria as assessed by BIRC review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Intracranial Response Rate (OIRR) in Cohort 1 by investigator review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Overall Intracranial Response Rate (OIRR) in Cohort 1, defined as the proportion of participants with a confirmed best intracranial overall response of Complete Response (CR) or Partial Response (PR) per RANO-BM criteria as assessed by investigator review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Disease Control Rate (IDCR) by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Intracranial Disease Control Rate (IDCR) per RANO-BM criteria as assessed by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to intracranial tumor Response (TTIR) by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Time to intracranial tumor Response (TTIR) per RANO-BM criteria as assessed by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Intracranial Response (DOIR) by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Duration of Intracranial Response (DOIR) per RANO-BM as assessed by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Intracranial Response Rate (OIRR) in Cohort 2 by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Overall Intracranial Response Rate (OIRR) per RANO-BM criteria in Cohort 2 by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Extracranial Response Rate (OERR) by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Overall Extracranial Response Rate (OERR) per RECIST 1.1 by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial Disease Control Rate (EDCR) by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Extracranial Disease Control Rate (EDCR) per RECIST 1.1 by investigator and BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Extracranial Response (TTER) by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Time to Extracranial Response (TTER) per RECIST 1.1 by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Extracranial Response (DOER) by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Duration of Extracranial Response (DOER) per RECIST 1.1 by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) per RECIST 1.1 by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Overall Response Rate (ORR) in the whole body per RECIST 1.1 by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR) by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Time to response (TTR) in the whole body per RECIST 1.1 by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Duration of response (DOR) in the whole body per RECIST 1.1 by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) by investigator and BIRC review</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Progression free survival (PFS) in the whole body per RECIST 1.1 by investigator review and by BIRC review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Overall survival (OS) is defined as the time from the date of start of treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Safety profile of capmatinib. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) including any clinically significant lab, vital signs, ECG abnormalities that are captured as an AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with dose interruptions</measure>
    <time_frame>Up to 29 months</time_frame>
    <description>Tolerability measured by the number of subjects who have interruptions of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with dose reductions</measure>
    <time_frame>Up to 29 months</time_frame>
    <description>Tolerability measured by the number of subjects who have reductions of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>Up to 29 months</time_frame>
    <description>Tolerability measured by the dose intensity of study drug computed as the ratio of actual cumulative dose received and actual duration of exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration in Functional Assessment of Cancer Therapy (FACT)-Brain Symptom Index (FBrSI) scores in Cohort 1</measure>
    <time_frame>Day 1 and 15 of Cycle 1, Day 1 of cycles 2 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days</time_frame>
    <description>Time to deterioration in symptoms of brain metastases in Cohort 1 with the Functional Assessment of Cancer Therapy (FACT)-Brain Symptom Index (FBrSI) (a standardized questionnaire developed to assess the quality of life of cancer patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in score as per FACT-Brain Symptom Index (FBrSI) in Cohort 2</measure>
    <time_frame>Day 1 and 15 of Cycle 1, Day 1 of cycles 2 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days</time_frame>
    <description>Change from baseline in symptoms of brain metastases in Cohort 2 with the FACT-Brain Symptom Index (FBrSI) (a standardized questionnaire developed to assess the quality of life of cancer patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30</measure>
    <time_frame>Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days</time_frame>
    <description>Change from baseline in lung cancer related symptoms, functioning and other domains of HRQoL in both cohorts with the EORTC QLQ-C30 (a 30-item questionnaire developed to assess the quality of life of cancer patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Lung Cancer Module (QLQ-LC13)</measure>
    <time_frame>Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days</time_frame>
    <description>Change from baseline in lung cancer related symptoms, functioning and other domains of HRQoL in both cohorts with the QLQ-LC13 (a 13-item questionnaire developed to assess the quality of life of cancer patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in score as per European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) questionnaire</measure>
    <time_frame>Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days</time_frame>
    <description>Change from baseline in lung cancer related symptoms, functioning and other domains of HRQoL in both cohorts with the EQ-5D-5L (a standardized questionnaire developed to assess the quality of life of cancer patients)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-small Cell Lung Carcinoma (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who are asymptomatic and without prior brain therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who are symptomatic with or without prior brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capmatinib</intervention_name>
    <description>400 mg administered orally twice daily</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed stage IV (according to Version 8 of the American Joint&#xD;
             Committee on Cancer (AJCC)) NSCLC that is EGFR wt, ALK rearrangement negative as&#xD;
             assessed by a validated test as part of the participant's standard of care and has&#xD;
             MET∆ex14 mutation per Novartis-designated central laboratory or (US only) locally with&#xD;
             FoundationOne Companion Diagnostic (F1CDx) .&#xD;
&#xD;
          -  Treatment naïve or up to two prior lines of systemic therapy for stage IIIb-IV NSCLC&#xD;
&#xD;
          -  Measurable intracranial lesions:&#xD;
&#xD;
               1. Cohort 1 and Cohort 2 (without leptomeningeal carcinoma): At least 1 measurable&#xD;
                  intracranial lesion per RANO-BM criteria, documented by a&#xD;
                  radiologist/neuroradiologist (treated or untreated).&#xD;
&#xD;
               2. Cohort 2 (with leptomeningeal carcinoma): participants with leptomeningeal&#xD;
                  carcinoma may not have measurable lesions. In this circumstance, the&#xD;
                  participant's disease will be considered to have non-target lesions only at&#xD;
                  baseline and their response based on descriptive clinical criteria by physician&#xD;
                  assessment.&#xD;
&#xD;
          -  Capable of undergoing magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Only for Cohort 1: any neurological symptoms related to brain metastases&#xD;
&#xD;
          -  For participants in Cohort 2 with prior brain therapy: Treatment with stereotactic&#xD;
             radiosurgery within 14 days prior to the start of study treatment or treatment with&#xD;
             WBRT within 14 days prior to the start of study treatment&#xD;
&#xD;
          -  Prior treatment with any MET targeting therapy or HGF inhibitor&#xD;
&#xD;
          -  Participants with other known druggable molecular alterations (such as ROS1&#xD;
             translocation or BRAF mutation) who might be candidates to alternative targeted&#xD;
             therapies as applicable per local regulations and treatment guidelines&#xD;
&#xD;
          -  Presence or history of ILD or interstitial pneumonitis, including clinically&#xD;
             significant radiation pneumonitis (i.e., affecting activities of daily living or&#xD;
             requiring therapeutic intervention)&#xD;
&#xD;
          -  Clinically significant, uncontrolled heart diseases including History of familial long&#xD;
             QT syndrome, sudden death or congenital long QT syndrome&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung carcinoma</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Treatment of lung cancer after first metastasi</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Lung adenocarcinoma</keyword>
  <keyword>Squamous cell lung carcinoma</keyword>
  <keyword>Large-cell lung carcinoma</keyword>
  <keyword>Large-cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04460729
org study id: CINC280A2203
nct id: NCT04460729
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to establish the intracranial efficacy of single agent
      capmatinib in the population of treatment-naïve or pretreated with one or two prior lines of
      systemic therapies for advanced stage Non Small-Cell Lung Cancer (NSCLC) with MET exon 14
      mutation that has metastasized to the brain.

      Cohort 1 (asymptomatic brain metastases (BM) without prior brain therapy) has been selected
      to identify patients who are most likely to benefit from capmatinib therapy in this setting
      and to establish a clinically relevant response outcome.

      Cohort 2 is a heterogeneous group of patients (symptomatic with and without prior brain
      therapy, asymptomatic with prior brain therapy, or with leptomeningeal disease.), and the
      outcomes will be descriptive only
This is a prospectively designed, multicenter, open-label, two-cohort, phase II study to
      evaluate the intracranial efficacy of single agent capmatinib in participants with MET exon
      14 mutated NSCLC and BM. Participants can be treatment naïve or pretreated with one or two
      prior lines of systemic therapies for advanced stage (stage IIIb - IV) NSCLC.

      Approximately 60 participants will be enrolled globally and allocated to one of two cohorts:

      Cohort 1 will enroll approximately 40 participants who are asymptomatic and without prior
      brain therapy.

      Cohort 2 will enroll approximately 20 participants who are symptomatic with or without prior
      brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease.

      All participants will be pre-screened for MET mutation and presence of BM will be documented
      at baseline by a radiologist/neuroradiologist.

      Intracranial disease will be assessed and response to treatment will be evaluated using the
      Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria every 8 weeks.
      Extracranial and whole body disease will be assessed and response to treatment will be
      evaluated using RECIST 1.1 every 8 weeks.

      Participants will receive capmatinib 400 mg b.i.d. until they experience any of the
      following: documented disease progression by RANO-BM criteria and/or RECIST 1.1 (as assessed
      by the investigator and confirmed by BIRC), withdrawal of consent, pregnancy, lost to
      follow-up, or death.

      For all participants, treatment with capmatinib may be continued beyond initial progression
      disease (PD) as per RANO-BM criteria and/or RECIST 1.1 (as assessed by the investigator and
      confirmed by BIRC) if, in the judgment of the investigator, there is evidence of clinical
      benefit, and the participant wishes to continue on the study treatment.

      After treatment discontinuation, all participants will be followed for safety evaluations
      during the safety follow-up period, and the participant's status will be collected every 12
      weeks as part of the survival follow-up.
allocation: Non-Randomized
intervention model: Parallel Assignment
intervention model description: Approximately 60 participants will be enrolled globally and allocated to one of two cohorts based on whether their metastatic brain disease is symptomatic or asymptomatic and with or without prior brain therapy or if they have been diagnosed with leptomeningeal disease
primary purpose: Treatment
masking: None (Open Label)
measure: Overall Intracranial Response Rate (OIRR) in Cohort 1 by Blinded Independent Review Committee (BIRC) review
time frame: Up to 36 months
description: Overall Intracranial Response Rate (OIRR) in Cohort 1, defined as the proportion of participants with a confirmed best intracranial overall response of Complete Response (CR) or Partial Response (PR) per RANO-BM criteria as assessed by BIRC review
measure: Overall Intracranial Response Rate (OIRR) in Cohort 1 by investigator review
time frame: Up to 36 months
description: Overall Intracranial Response Rate (OIRR) in Cohort 1, defined as the proportion of participants with a confirmed best intracranial overall response of Complete Response (CR) or Partial Response (PR) per RANO-BM criteria as assessed by investigator review
measure: Intracranial Disease Control Rate (IDCR) by investigator and BIRC review
time frame: Up to 36 months
description: Intracranial Disease Control Rate (IDCR) per RANO-BM criteria as assessed by investigator review and by BIRC review
measure: Time to intracranial tumor Response (TTIR) by investigator and BIRC review
time frame: Up to 36 months
description: Time to intracranial tumor Response (TTIR) per RANO-BM criteria as assessed by investigator review and by BIRC review
measure: Duration of Intracranial Response (DOIR) by investigator and BIRC review
time frame: Up to 36 months
description: Duration of Intracranial Response (DOIR) per RANO-BM as assessed by investigator review and by BIRC review
measure: Overall Intracranial Response Rate (OIRR) in Cohort 2 by investigator and BIRC review
time frame: Up to 36 months
description: Overall Intracranial Response Rate (OIRR) per RANO-BM criteria in Cohort 2 by investigator review and by BIRC review
measure: Overall Extracranial Response Rate (OERR) by investigator and BIRC review
time frame: Up to 36 months
description: Overall Extracranial Response Rate (OERR) per RECIST 1.1 by investigator review and by BIRC review
measure: Extracranial Disease Control Rate (EDCR) by investigator and BIRC review
time frame: Up to 36 months
description: Extracranial Disease Control Rate (EDCR) per RECIST 1.1 by investigator and BIRC review
measure: Time to Extracranial Response (TTER) by investigator and BIRC review
time frame: Up to 36 months
description: Time to Extracranial Response (TTER) per RECIST 1.1 by investigator review and by BIRC review
measure: Duration of Extracranial Response (DOER) by investigator and BIRC review
time frame: Up to 36 months
description: Duration of Extracranial Response (DOER) per RECIST 1.1 by investigator review and by BIRC review
measure: Overall Response Rate (ORR) per RECIST 1.1 by investigator and BIRC review
time frame: Up to 36 months
description: Overall Response Rate (ORR) in the whole body per RECIST 1.1 by investigator review and by BIRC review
measure: Time to response (TTR) by investigator and BIRC review
time frame: Up to 36 months
description: Time to response (TTR) in the whole body per RECIST 1.1 by investigator review and by BIRC review
measure: Duration of response (DOR) by investigator and BIRC review
time frame: Up to 36 months
description: Duration of response (DOR) in the whole body per RECIST 1.1 by investigator review and by BIRC review
measure: Progression free survival (PFS) by investigator and BIRC review
time frame: Up to 36 months
description: Progression free survival (PFS) in the whole body per RECIST 1.1 by investigator review and by BIRC review
measure: Overall survival (OS)
time frame: Up to 36 months
description: Overall survival (OS) is defined as the time from the date of start of treatment to the date of death due to any cause.
measure: Percentage of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs)
time frame: Up to 36 months
description: Safety profile of capmatinib. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) including any clinically significant lab, vital signs, ECG abnormalities that are captured as an AE
measure: Number of participants with dose interruptions
time frame: Up to 29 months
description: Tolerability measured by the number of subjects who have interruptions of study treatment
measure: Number of participants with dose reductions
time frame: Up to 29 months
description: Tolerability measured by the number of subjects who have reductions of study treatment
measure: Dose intensity
time frame: Up to 29 months
description: Tolerability measured by the dose intensity of study drug computed as the ratio of actual cumulative dose received and actual duration of exposure
measure: Time to deterioration in Functional Assessment of Cancer Therapy (FACT)-Brain Symptom Index (FBrSI) scores in Cohort 1
time frame: Day 1 and 15 of Cycle 1, Day 1 of cycles 2 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
description: Time to deterioration in symptoms of brain metastases in Cohort 1 with the Functional Assessment of Cancer Therapy (FACT)-Brain Symptom Index (FBrSI) (a standardized questionnaire developed to assess the quality of life of cancer patients)
measure: Change from baseline in score as per FACT-Brain Symptom Index (FBrSI) in Cohort 2
time frame: Day 1 and 15 of Cycle 1, Day 1 of cycles 2 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
description: Change from baseline in symptoms of brain metastases in Cohort 2 with the FACT-Brain Symptom Index (FBrSI) (a standardized questionnaire developed to assess the quality of life of cancer patients)
measure: Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30
time frame: Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
description: Change from baseline in lung cancer related symptoms, functioning and other domains of HRQoL in both cohorts with the EORTC QLQ-C30 (a 30-item questionnaire developed to assess the quality of life of cancer patients)
measure: Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Lung Cancer Module (QLQ-LC13)
time frame: Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
description: Change from baseline in lung cancer related symptoms, functioning and other domains of HRQoL in both cohorts with the QLQ-LC13 (a 13-item questionnaire developed to assess the quality of life of cancer patients)
measure: Change from baseline in score as per European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) questionnaire
time frame: Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
description: Change from baseline in lung cancer related symptoms, functioning and other domains of HRQoL in both cohorts with the EQ-5D-5L (a standardized questionnaire developed to assess the quality of life of cancer patients)
arm group label: Cohort 1
arm group type: Experimental
description: Participants who are asymptomatic and without prior brain therapy
arm group label: Cohort 2
arm group type: Experimental
description: Participants who are symptomatic with or without prior brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease
intervention type: Drug
intervention name: Capmatinib
description: 400 mg administered orally twice daily
arm group label: Cohort 1
arm group label: Cohort 2
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Novartis Pharmaceuticals
role: Study Director
affiliation: Novartis Pharmaceuticals
responsible party type: Sponsor
mesh term: Carcinoma
mesh term: Lung Neoplasms
mesh term: Carcinoma, Non-Small-Cell Lung
sharing ipd: Yes
ipd description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com